ReviewThe Journal of endocrinology2026
Fat's all, folks: culturing and manipulating peri-prostatic adipocytes to probe impacts on prostate cancer biology.
Review in The Journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity, officially recognised as a global epidemic by the World Health Organization, will soon overtake smoking as the largest preventable risk factor for cancer. By 2035, more than half the world's population is expected to be overweight or obese with a significant increase in obesity-related health expenditures. However, despite the increase in prevalence and the overall lower life expectancy associated with obesity, mechanisms underpinning obesity-driven diseases are not well understood. Adipocytes pose many challenges for in vitro culture due to their poor cell-to-surface attachment and low viability. Their large size and high lipid content can also present methodological challenges for downstream experiments. Several mouse and human-derived primary pre-adipocyte cell lines have been established over the years. However, they show limited renewal capacity and they cannot be cultured long term in vitro. Commercial cell lines available, which can be cultured long term, fail to represent organ-specific adipocyte heterogeneity. Adipose tissue from different organs and fat depots can show significant heterogeneity in terms of metabolism and overall secretome and extracellular matrix production. The prostate, for example, is surrounded by peri-prostatic adipose tissue (PPAT), the volume of which is associated with an increased risk of lethal prostate cancer and a reduced therapy response. Here, we outline a protocol for ex vivo culture of fresh PPAT and non-prostatic adipose tissue (NPAT), which reflects donor- and depot-specific characteristics. Ex vivo culture of PPAT/NPAT explants maintains cell-cell interactions and preserves local tissue architecture within adipose tissue. We have also described establishment of immortalised, patient PPAT-derived pre-adipocytes and patient-matched NPAT pre-adipocytes that can be in vitro differentiated into mature adipocytes. The protocols outlined here could be readily adapted to other organ-specific fat depots, such as mammary/bone marrow adipose tissue, and to tissues of non-human origin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.